PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Zidovudine - HIV infection
PAD Profile : Zidovudine - HIV infection
Keywords :
antiviral
Brand Names Include :
Retrovir
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Abacavir
- Abacavir and lamivudine
- Abacavir/lamivudine/zidovudine
- Abacavir/lamivudine/zidovudine
- Amprenavir
- Atazanavir
- Atazanavir and cobicistat
- Cobicistat
- Darunavir
- Darunavir/cobicistat
- Didanosine
- Dolutegravir
- Efavirenz
- Emtricitabine
- Emtricitabine and tenofovir alafenamide
- Fosamprenavir calcium
- Indinavir
- Lamivudine
- Lamivudine
- Ramipril
- Lopinavir and ritonavir
- Ritonavir
- Saquinavir mesylate
- Stavudine
- Emtricitabine and tenofovir disoproxil
- Tipranavir
- Lamivudine and zidovudine
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
04 September 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
These drugs falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication
Associated BNF Codes
05. Infections
05.03.01. HIV infection